Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Chemotherapy for Gynecologic Cancers Occurring During Pregnancy

Ko, Emily M. MD*; Van Le, Linda MD

Obstetrical & Gynecological Survey: May 2011 - Volume 66 - Issue 5 - p 291-298
doi: 10.1097/OGX.0b013e318224e877

Chemotherapy treatment of gynecologic malignancies during pregnancy should provide maternal benefit without undue fetal harm. We review the treatment regimens for gynecologic cancers occurring during pregnancy and the effects of chemotherapy on fetal development, parturition, and lactation. Women diagnosed with a gynecologic cancer during pregnancy require individualized treatment plans from a multidisciplinary team.

Target Audience: Obstetricians & Gynecologists, Family Physicians

Learning Objectives: After completing this CME activity, physicians should be better able to specify the indications for chemotherapy in gynecologic cancers during pregnancy and postpartum periods, discuss the risks and benefits of chemotherapy for gynecologic cancer during pregnancy and postpartum periods. In addition, they should also be able to distinguish the mechanism of action of various chemotherapy agents to choose the best treatment options for patients and monitor for impacts of chemotherapy on fetal growth to determine the best treatment and management strategies.

*Gynecologic Oncology Fellow,†Professor, University of North Carolina, Division of Gynecologic Oncology, Chapel Hill, NC

Chief Editor's Note: This article is part of a series of continuing education activities in this Journal through which a total of 36 AMA/PRA Category 1 Credits™ can be earned in. Instructions for how CME credits can be earned appear on the last page of the Table of Contents.

The authors, faculty and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interest in, any commercial organizations pertaining to this educational activity.

Correspondence requests to: Linda Van Le, MD, UNC Division of Gynecologic Oncology, Physicians Office Building, Room B103, 170 Manning Drive, Campus Box 7572, Chapel Hill, NC 27599. E-mail:

© 2011 Lippincott Williams & Wilkins, Inc.